Day: March 21, 2024

Cellebrite Files its 2023 Annual Report on Form 20-F

Written by Customer Service on March 21, 2024. Posted in Public Companies.

TYSONS CORNER, Va. and PETAH TIKVA, Israel, March 21, 2024 (GLOBE NEWSWIRE) — Cellebrite DI Ltd. (Nasdaq: CLBT), a leader in premier Digital Investigative solutions for the public and private sectors, today announced that the Company has filed its Annual Report on Form 20-F for the year ended December 31, 2023, with the U.S. Securities and Exchange Commission (the “SEC”). Cellebrite’s 2023 Annual Report on Form 20-F is available on the investor relations section of its website at https://investors.cellebrite.com/financial-information/sec-filings and on the SEC’s website at www.sec.gov. Shareholders may request a hard copy of the 2023 Annual Report on Form 20-F, free of charge, by contacting the Company at investors@cellebrite.com. About Cellebrite Cellebrite’s (Nasdaq: CLBT) mission is to enable its customers to protect and save...

USDA-APHIS Determines that Yield10 Bioscience’s Omega-3 Camelina Varieties May Be Planted and Bred in the United States

Written by Customer Service on March 21, 2024. Posted in Public Companies.

-Yield10 achieves significant milestone enabling ramp-up to commercial scale production of omega-3 fatty acids in Camelina -Omega-3 Camelina potentially represents a novel solution to the market need for omega-3 oils used in aquafeed for farmed fish and in human nutrition WOBURN, Mass., March 21, 2024 (GLOBE NEWSWIRE) — Yield10 Bioscience, Inc. (Nasdaq:YTEN) (“Yield10” or the “Company”), an agricultural bioscience company, today announced that USDA-APHIS’s Biotechnology Regulatory Services (“BRS”) has determined that Yield10’s Camelina sativa (“Camelina”) varieties developed using genetic engineering (modified Camelina) to produce omega-3 fatty acids are not subject to the regulations under 7 CFR part 340, and may be grown and bred in the United States. The global markets for omega-3 fatty acids include aquafeed used for...

Willis Lease Finance Corporation Completes Delivery of 4th ATR 72-500 Aircraft under its ConstantThrust® Engine Maintenance Program

Written by Customer Service on March 21, 2024. Posted in Public Companies.

COCONUT CREEK, Fla., March 21, 2024 (GLOBE NEWSWIRE) — Willis Lease Finance Corporation (NASDAQ: WLFC) (“WLFC”) announces it has successfully delivered its fourth ATR 72-500 aircraft to Transportes Aéreos Guatemaltecos (TAG Airlines) (“TAG”) as part of its lease agreements with the airline for four ATR 72-500 aircraft. The aircraft were overhauled and refurbished and fitted with new Pratt & Whitney Canada PW127M engines. Under the lease agreements, the aircraft are included in WLFC’s ConstantThrust® program for PW127M engines. WLFC will oversee the maintenance and care for the engines and will provide replacement engines as applicable. “We are thrilled to support TAG, our first regional ConstantThrust® airline partner, with a fourth aircraft delivery,” said Austin C. Willis, Chief Executive Officer of WLFC. “We value the relationship...

Intuitive Machines Reports Fourth Quarter and Full Year 2023 Financial Results

Written by Customer Service on March 21, 2024. Posted in Earnings Releases And Operating Results.

Delivered NASA and commercial payloads to the moon further south than any vehicle in history, marking the United States’ first lunar landing in over 50 years, on February 22, 2024 Supported by the FY 2024 NASA budget passed on March 8, 2024, Intuitive Machines contracts for CLPS and OMES III, as well as key future Artemis campaign contracts NSNS and LTVS were fully funded Validated the performance of the Company’s proprietary liquid methane and liquid oxygen propulsion system through the first-ever deep space ignition, resulting in a 7-day mission from launch to the lunar surface in Q1 Earned mission completion milestone payments from NASA and commercial customers of approximately $12.5 million following more than 144 hours of lunar surface operations Concluded 2023 with $268.6 million in backlog which nearly doubled in Q4 driven by...

Nano Dimension Announces Record 2023 Revenue of $56.3 Million and Organic Growth of 29%

Written by Customer Service on March 21, 2024. Posted in Earnings Releases And Operating Results.

Gross Margin Grew 41%; 45% vs. 32% Year-Over-Year Q4/2023 Revenue Grew 19% vs. Q4/2022 Conference Call to be Held Today at 9:00 AM EDT WALTHAM, Mass., March 21, 2024 (GLOBE NEWSWIRE) — Nano Dimension Ltd. (Nasdaq: NNDM, “Nano Dimension” or the “Company”), a leading supplier of Additively Manufactured Electronics (“AME”) and multi-dimensional polymer, metal & ceramic Additive Manufacturing (“AM”), today announced financial results for the fourth quarter and full year ended December 31st, 2023. RevenueQ4/2023: $14.5 million, up 19% compared to Q4/ 2022 FY 2023: $56.3 million, up 29% compared to FY 2022Gross Margin (“GM”)FY 2023: 45%; up 41% from 32% in FY 2022Adjusted1 Gross Margin (“Adjusted GM”)FY 2023: 48%; vs. 46% in FY 2022Net Cash Burn² down 42% from 2022 to 2023:FY 2022: $146 million FY 2023: $84 million FY...

Knight Therapeutics Reports Fourth Quarter and Year-End 2023 Results

Written by Customer Service on March 21, 2024. Posted in Earnings Releases And Operating Results.

Achieved Record Annual Revenues and EBITDA MONTREAL, March 21, 2024 (GLOBE NEWSWIRE) — Knight Therapeutics Inc. (TSX: GUD) (“Knight” or “the Company”), a leading pan-American (ex-US) specialty pharmaceutical company, today reported financial results for its fourth quarter and year ended December 31, 2023. All currency amounts are in thousands except for share and per share amounts. All currencies are Canadian unless otherwise specified. 2023 Highlights Financial resultsRevenues were $328,199, an increase of $34,636 or 12% over prior year. Revenues excluding IAS 29 were $343,138, an increase of $51,368 or 18% over prior year. Gross margin was $152,652 or 47% compared to $138,061 or 47% in prior year. Adjusted EBITDA1 was $60,075, an increase of $6,043 or 11% over prior year. Adjusted EBITDA per share1 was $0.59, an...

Pyxis Oncology Provides Corporate Update and Reports Financial Results for Fourth Quarter and Full Year 2023

Written by Customer Service on March 21, 2024. Posted in Earnings Releases And Operating Results.

Figure 1Dose escalation and subject numbers by dose since initiating the trial in March 2023PYX-201 Phase 1 Part 1 trial progressing with initial data expected in the fall of 2024 PYX-106 Phase 1 trial progressing with initial data expected 2H 2024 Completed $50 million private placement Expected cash runway into 2H 2026 BOSTON, March 21, 2024 (GLOBE NEWSWIRE) — Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, today reported financial results for the year and quarter ended December 31, 2023, and provided a corporate update. PYX-201, a first-in-concept tumor stroma targeting antibody-drug conjugate (ADC) against the stromal Extradomain-B Fibronectin (EDB+FN) target, has dosed 37 patients in 6 cohorts since initiating the...

Creative Realities Reports Fiscal 2023 Fourth Quarter Results

Written by Customer Service on March 21, 2024. Posted in Earnings Releases And Operating Results.

Record Revenue, Gross Profit, and Adjusted EBITDA for Quarter and Year LOUISVILLE, Ky., March 21, 2024 (GLOBE NEWSWIRE) — Creative Realities, Inc. (“Creative Realities,” “CRI,” or the “Company”) (NASDAQ: CREX), a leading provider of digital signage and media solutions, announced its financial results for the fiscal fourth quarter and year ended December 31, 2023. Highlights:All-time record revenue of $14.5 million ($15.4 million*) and $45.2 million ($46.1 million*) for the fourth quarter and full year 2023, respectively All-time record gross profit of $7.5 million and $22.2 million for the fourth quarter and full year 2023, respectively All-time record Adjusted EBITDA** of $2.8 million and $5.1 million for the fourth quarter and full year 2023, respectively Annual recurring revenue (“ARR”) rose to an all-time high of a $16.3...

Absci Reports Business Updates and Fourth Quarter and Full Year 2023 Financial and Operating Results

Written by Customer Service on March 21, 2024. Posted in Earnings Releases And Operating Results.

Initiated IND-enabling studies for ABS-101, a potential best-in-class anti-TL1A antibody Entered into collaboration with AstraZeneca for up to $247M in deal value, plus royalties Strengthened balance sheet raising approximately $86M in gross proceeds through underwritten common stock offering VANCOUVER, Wash. and NEW YORK, March 21, 2024 (GLOBE NEWSWIRE) — Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today reported financial and operating results for the fourth quarter and year ended December 31, 2023. “In 2023, Absci further solidified its leadership in AI-driven biologic drug discovery,” said Sean McClain, Founder and CEO. “Our breakthroughs in generative AI drug creation have rapidly translated into a differentiated internal portfolio of potential best-in-class and first-in-class...

IntelGenx Reports Fourth Quarter and Full-Year 2023 Financial Results

Written by Customer Service on March 21, 2024. Posted in Earnings Releases And Operating Results.

SAINT LAURENT, Quebec, March 21, 2024 (GLOBE NEWSWIRE) — IntelGenx Technologies Corp. (TSX:IGX)(OTCQB:IGXT) (the “Company” or “IntelGenx”) today reported financial results for the three- and twelve-month periods ended December 31, 2023. All dollar amounts are expressed in U.S. currency, unless otherwise indicated, and results are reported in accordance with United States generally accepted accounting principles except where noted otherwise. “We successfully executed against key strategic priorities in 2023, the most important of which was to lay the groundwork for our product pipeline and services portfolio to start generating significant revenues in 2024,” commented Dwight Gorham, IntelGenx’s CEO. “To that end, we expect that our commercial partner for RIZAFILM®1, Gensco Pharma, will be launching...

Day: March 21, 2024

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Cookie Notice